Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the international letrozole breast cancer group

被引：23

作者：

Buzdar, AU ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 15期

关键词：

D O I：

10.1200/JCO.2004.99.058

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3199 / 3200

页数：2

共 50 条

[1] Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women:: Analysis of survival and update of efficacy from the international letrozole breast cancer group
Mouridsen, H
Gershanovick, M
Sun, Y
Pérez-Carrión, R
Boni, C
Monnier, A
Apffelstaedt, J
Smith, R
Sleeboom, HP
Jaenicke, F
Pluzanska, A
Dank, M
Becquart, D
Bapsy, PP
Salminen, E
Snyder, R
Chaudri-Ross, H
Lang, R
Wyld, P
Bhatnagar, A
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (11) : 2101 - 2109
[2] Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the international letrozole breast cancer group - Reply
Mouridsen, H
Chaudri-Ross, HA
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (15) : 3200 - 3201
[3] Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group
Illiger, HJ
STRAHLENTHERAPIE UND ONKOLOGIE, 2002, 178 (02) : 111 - 113
[4] Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer:: Results of a phase III study of the international letrozole breast cancer group
Mouridsen, H
Gershanovich, M
Sun, Y
Pérez-Carrión, R
Boni, C
Monnier, A
Apffelstaedt, J
Smith, R
Sleeboom, HP
Jänicke, F
Pluzanska, A
Dank, M
Becquart, D
Bapsy, PP
Salminen, E
Snyder, R
Lassus, M
Verbeek, JA
Staffler, B
Chaudri-Ross, HA
Dugan, M
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) : 2596 - 2606
[5] Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group (vol 19, pg 2596, 2001)
Mouridsen
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) : 3302 - 3302
[6] Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer
Mouridsen, H
Chaudri-Ross, HA
ONCOLOGIST, 2004, 9 (05): : 497 - 506
[7] A Stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy - For advanced breast cancer in postmenopausal patients
Karnon, J
Jones, T
PHARMACOECONOMICS, 2003, 21 (07) : 513 - 525
[8] A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy for advanced breast cancer in postmenopausal patients in Germany
Fricke, FU
Quednau, K
Pirk, O
VALUE IN HEALTH, 2002, 5 (06) : 443 - 443
[9] A Stochastic Economic Evaluation of Letrozole versus Tamoxifen as a First-Line Hormonal TherapyFor Advanced Breast Cancer in Postmenopausal Patients
Jon Karnon
Trefor Jones
PharmacoEconomics, 2003, 21 : 513 - 525
[10] Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women
Vergote, I
Bonneterre, J
Thürlimann, B
Robertson, J
Krzakowski, M
Mauriac, L
Koralewski, L
Webster, A
Steinberg, M
von Euler, M
EUROPEAN JOURNAL OF CANCER, 2000, 36 : S84 - S85

← 1 2 3 4 5 →